Pliant Therapeutics, Inc. (PLRX) Stock

Pliant Therapeutics, Inc. (PLRX) is a Healthcare stock trading at $1.16 (as of 2026-08-21), with a market capitalization of $71.52M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Understand Pliant Therapeutics, Inc.: how it makes money

Pliant Therapeutics is a clinical stage biopharmaceutical company developing oral small-molecule therapies for fibrosis-related diseases in the United States, aiming to make money by commercializing successful candidates after clinical development and regulatory approval.

Because Pliant is clinical stage, its profit model is fundamentally driven by the ability to turn Phase 2a and Phase 1 clinical progress for its lead integrin inhibitor candidates (PLN-74809 and PLN-1474) into an approvable, commercial product.

Business quality (Weak): The operating story is supported by multiple ongoing Phase 2a efforts for PLN-74809 and at least one Phase 1 completion for PLN-1474, with detailed clinical readouts tracked by specific study metrics (including duration without severe or serious treatment-related adverse events and efficacy comparisons to placebo). The main limitation for investors is that none of the provided information indicates products are yet approved or generating meaningful commercial revenue.

Bull case

  • Multiple clinical tracks for the lead program: PLN-74809 is in three Phase 2a trials, providing several shots on goal within the fibrosis treatment pipeline.
  • Progression of readouts with longer follow-up: INTEGRIS-PSC has Number of Weeks of INTEGRIS-PSC Data Reported (Twenty-Four-Week Data) of 24.0, reflecting more than just very short-term observation.
  • Tolerability signal highlighted in the tracked metric set: Bexotegrast Treatment Duration without severe or serious treatment-related adverse events is tracked at 40.0 weeks.

Bear case

  • Clinical-stage execution risk remains high: The lead candidate is still in Phase 2a, and the second candidate PLN-1474 has completed Phase 1 but is not yet shown as approved, so outcomes could change as studies progress.
  • Early trial signals may not translate across endpoints and studies: The provided operational metrics include placebo comparisons and tumor response measures, but these are still derived from ongoing trial cohorts rather than confirmed commercial outcomes.
  • Sample sizes in the tracked cohorts can be limited: The KPI set includes smaller cohort counts (for example, INTEGRIS-PSC 320 Milligram Cohort Trial Size (Patients) of 28.0, with 27.0 in the 320 milligram active arm and 9.0 in the placebo arm), which can increase uncertainty.
Valuation — source: SEC EDGAR (first-party)
Price$1.16
Market Cap$71.52M
Price / Book0.49
FCF Yield-253.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)26.2%
FCF Growth (YoY)35.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.70 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderTANG CAPITAL MANAGEMENT LLC ($7.74M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOBernard Coulie
Employees171
CountryUS
IPO Date2020-06-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Serina Therapeutics, Inc. (SER)
  • iBio, Inc. (IBIO)
  • Rein Therapeutics Inc. (RNTX)
  • Spero Therapeutics, Inc. (SPRO)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • XBiotech Inc. (XBIT)
  • OS Therapies Incorporated (OSTX)
  • MediciNova, Inc. (MNOV)
PLRX earnings history · PLRX institutional & insider holders · PLRX KPIs & operating metrics · PLRX financials · PLRX investor presentations & press releases · PLRX SEC filings · PLRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.